# The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/the-rituximab-biosimilar-ct-p10-in-rheumatology-and-cancer-a-budget-impact/

## Facts

| Field | Value |
| --- | --- |
| Author Names | László Gulàcsi,Valentin Brodszky,Petra Baji,Fanni Rencz,Márta Péntek |
| Citations | 79 |
| DOI | 10.1007/s12325-017-0522-y |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s12325-017-0522-y.pdf |
| OpenAlex ID | https://openalex.org/W2606245581 |
| PMID | 28397080 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Fanni Rencz](https://scholariq.org/researchers/fanni-rencz/)

## Paper journal

- [Advances in Therapy](https://scholariq.org/journals/advances-in-therapy/)

## Paper primary topic

- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Paper topics

- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.